Contineum Therapeutics, Inc. (CTNM) Financial Statements
Free cash flow over the same period: -$53.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CTNMContineum Therapeutics, Inc.Follow CTNM — free
—
Price chart with a free account
- Market cap
- 312.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Research & development | 38.4 | 51.5 | 48.1 | |
| Operating income | -50.9 | -68.1 | -66.4 | |
| Pre-tax income | -42.3 | -60.1 | -57.6 | |
| Income tax | 0.0 | 0.0 | — | |
| Net income | -42.3 | -60.0 | -57.6 | |
| Diluted EPS ($) | -2.18 | -2.17 | -1.72 | |
| Diluted shares (mn) | 19.4 | 27.7 | — |
USD millions · SEC XBRL
Contineum Therapeutics, Inc. — questions
- What is Contineum Therapeutics, Inc.'s net income?
- -$57.6M over the twelve months to 2026-06-30.
- What is Contineum Therapeutics, Inc.'s free cash flow?
- -$53.5M over the twelve months to 2026-06-30.
- What are Contineum Therapeutics, Inc.'s diluted earnings per share?
- $-1.72 over the twelve months to 2026-06-30.
Every figure on this page comes from Contineum Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.